Press Releases Latest Mar 14, 2023 Theratechnologies to Present Preclinical Data at AACR Demonstrating Synergy Between TH1902 and Anti-PD-L1 Immunotherapy in Cold Tumor Model Press Releases Year None20232022202120202019201820172016201520142013 Oct 13, 2022 Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update Oct 12, 2022 Theratechnologies Presents Data Demonstrating High Expression of Sortilin (SORT1) in Multiple Tumor Types at 34th EORTC-NCI-AACR Symposium Oct 03, 2022 Theratechnologies’ Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population Sep 26, 2022 Theratechnologies to Announce Third Quarter 2022 Financial Results and Provide Business Update Sep 19, 2022 Theratechnologies to Present at the Cantor Oncology, Hematology & HemeOnc Conference Sep 12, 2022 Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Aug 02, 2022 Theratechnologies to Present at the Canaccord Genuity 42nd Annual Growth Conference Jul 28, 2022 Theratechnologies Trogarzo® Data at AIDS 2022 Shows Potential for Improved Treatment Regimens Jul 27, 2022 Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement Jul 14, 2022 Theratechnologies Reports Second Quarter and First Half Fiscal 2022 Financial Results and Provides Business Update First page « Previous page ‹ Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page › Last page » Displaying 11 - 20 of 305
Mar 14, 2023 Theratechnologies to Present Preclinical Data at AACR Demonstrating Synergy Between TH1902 and Anti-PD-L1 Immunotherapy in Cold Tumor Model
Oct 13, 2022 Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update
Oct 12, 2022 Theratechnologies Presents Data Demonstrating High Expression of Sortilin (SORT1) in Multiple Tumor Types at 34th EORTC-NCI-AACR Symposium
Oct 03, 2022 Theratechnologies’ Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population
Sep 26, 2022 Theratechnologies to Announce Third Quarter 2022 Financial Results and Provide Business Update
Sep 12, 2022 Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth
Jul 28, 2022 Theratechnologies Trogarzo® Data at AIDS 2022 Shows Potential for Improved Treatment Regimens
Jul 27, 2022 Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement
Jul 14, 2022 Theratechnologies Reports Second Quarter and First Half Fiscal 2022 Financial Results and Provides Business Update
